COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Jonas Björk, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Malin Inghammar, Fredrik Kahn
doi: https://doi.org/10.1101/2022.04.14.22273896

Article usage

Article usage: April 2022 to November 2024

AbstractFullPdf
Apr 2022259373628
May 2022333896
Jun 2022157242
Jul 2022139744
Aug 202291316
Sep 20226208
Oct 202256213
Nov 20224607
Dec 20222718
Jan 20232103
Feb 20233037
Mar 20232417
Apr 20232913
May 20231713
Jun 20231443
Jul 2023514
Aug 202323106
Sep 20233642
Oct 20232953
Nov 20232132
Dec 20232114
Jan 20241844
Feb 20241103
Mar 20241866
Apr 20241845
May 20241144
Jun 20241414
Jul 20241204
Aug 20242228
Sep 20241866
Oct 20241126
Nov 20241007
Back to top
Posted April 18, 2022.
Download PDF

Supplementary Material

Data/Code
Email
COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
Jonas Björk, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Malin Inghammar, Fredrik Kahn
medRxiv 2022.04.14.22273896; doi: https://doi.org/10.1101/2022.04.14.22273896
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area